key: cord-0998838-ddt2um2s
authors: Novazzi, Federica; Baj, Andreina; Pasciuta, Renee; Genoni, Angelo; Ferrante, Francesca Drago; Tripiciano, Rosalia; Catanoso, Giuseppe; Focosi, Daniele; Maggi, Fabrizio
title: A CLUSTER OF SARS-COV-2 DELTA VARIANT OF CONCERN ADDITIONALLY HARBORING F490S, NORTHERN LOMBARDY, ITALY
date: 2022-01-04
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.12.362
sha: bfb321c7273381d48206acfa5464ece9264fc8da
doc_id: 998838
cord_uid: ddt2um2s

The Delta variant of concern (VOC) of SARS-CoV-2 has become dominant worldwide. We report here a cluster caused by B.1.617.2 harboring the additional mutation of concern (MOC) F490S. Infection occurred in 5 fully vaccinated subjects between the ages of 47 and 84. The immune escape mutation F490S, first identified in the Lambda VOI, appears to impair vaccine efficacy and is rapidly increasing in prevalence worldwide.

Since the beginning of 2021, a SARS-CoV-2 lineage originally described in India has become the predominant circulating variant of the COVID-19 pandemic. Such variant of concern (VOC) was renamed "Delta" by WHO, VOC-21APR-02 by Public Health England, 21A/S:478K by NextStrain, and G/452R.V3 by GISAID. The most refined nomenclature has been proposed by PANGOlin, which recognizes sublineages ranging from AY.1 to AY.117.

T478K and L452R are the main mutations of concern (MOC) within the Spike protein of Delta.

We report here a cluster of B.1.617.2 + F490S occurring in two families living in the same small town in Northern Lombardy. All cases were first tested by real-time RT-PCR, and, if positive, sequenced by NGS as previously reported (Liu Z et al., 2021) .

Overall, the cluster was of 6 subjects who tested SARS-CoV-2 RNA positive between 

L18F substrain of SARS-CoV

VOC-202012/01 is rapidly spreading in England

Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

immunocompromised host displaying treatment-induced viral evolution

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

"This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors." SARS-CoV-2 RT-PCR and sequencing were performed according to the surveillance program of the Italian National Institute of Health and Ministry of Health.